

Global Radionuclide Drug Conjugate(RDC) Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/G16D51315A3FEN.html>

Date: January 2026

Pages: 133

Price: US\$ 3,660.00 (Single User License)

ID: G16D51315A3FEN

Abstracts

The global Radionuclide Drug Conjugate(RDC) market size is predicted to grow from US\$ 10500 million in 2025 to US\$ 20170 million in 2032; it is expected to grow at a CAGR of 10.0% from 2026 to 2032.

Radionuclide-conjugated drugs (RCDs) are a novel type of therapeutic drug combining precise targeting and potent killing. Their structure is similar to antibody-drug conjugates (ADCs), but the toxic payload is replaced by a radionuclide. They mainly consist of four parts: a targeting ligand responsible for specific tumor recognition, a linker arm, a chelating agent to stabilize the bound radionuclide, and the radionuclide itself. After entering the body, the ligand guides the radionuclide to precisely accumulate at the tumor site. The radiation released during radionuclide decay destroys tumor cell DNA from within, achieving highly effective treatment. If imaging radionuclides are used, they can be used for tumor localization and diagnosis.

The market prospects for RCDs are extremely broad, leading to the rapid rise of the radiopharmaceutical industry. The core drivers of future growth lie in technological iteration and application expansion: therapeutic radionuclides are upgrading from current α -radionuclides to next-generation α -radionuclides with stronger and more precise killing power; indications are expanding from prostate cancer and neuroendocrine tumors to more solid tumors and even non-tumor fields. With policy support and capital investment, pharmaceutical companies from various countries are vying to break through bottlenecks in the industrial chain, such as isotope supply, production and distribution. The unique advantages of integrated diagnosis and treatment will make RDC an important pillar for precision cancer treatment.

LPI (LP Information)' newest research report, the "Radionuclide Drug Conjugate(RDC)

Industry Forecast” looks at past sales and reviews total world Radionuclide Drug Conjugate(RDC) sales in 2025, providing a comprehensive analysis by region and market sector of projected Radionuclide Drug Conjugate(RDC) sales for 2026 through 2032. With Radionuclide Drug Conjugate(RDC) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Radionuclide Drug Conjugate(RDC) industry.

This Insight Report provides a comprehensive analysis of the global Radionuclide Drug Conjugate(RDC) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Radionuclide Drug Conjugate(RDC) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Radionuclide Drug Conjugate(RDC) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Radionuclide Drug Conjugate(RDC) and breaks down the forecast by Target Ligand Types, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Radionuclide Drug Conjugate(RDC).

This report presents a comprehensive overview, market shares, and growth opportunities of Radionuclide Drug Conjugate(RDC) market by product type, application, key players and key regions and countries.

Segmentation by Target Ligand Types:

Antibody-Drug Conjugates (ARC)

Peptide-Drug Conjugates (PRC)

Small Molecule-Drug Conjugates (SMRC)

Segmentation by Medical Uses:

Diagnostic RDCs

Therapeutic RDCs

Segmentation by Therapeutic Radionuclide Properties:

?-Nuclear Therapy

?-Nuclear Therapy

Segmentation by Application:

Prostate Cancer

Neuroendocrine Tumors

Liver Cancer

Kidney Cancer

Bone Metastases

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered

from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Novartis

Bayer

AstraZeneca

Eli Lilly

Bristol-Myers Squibb

Johnson & Johnson

Grand Pharmaceutical Group

China Isotope & Radiation Corporation

Dongcheng Pharmaceutical

Hengrui Medicine

Xiantong Pharmaceutical

Bivision

SmartNuclide

Full-Life Technologies

Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.

Nuoyu Pharmaceutical

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Radionuclide Drug Conjugate(RDC) Market Size (2021-2032)
- 2.1.2 Radionuclide Drug Conjugate(RDC) Market Size CAGR by Region (2021 VS 2025 VS 2032)
- 2.1.3 World Current & Future Analysis for Radionuclide Drug Conjugate(RDC) by Country/Region (2021, 2025 & 2032)

2.2 Radionuclide Drug Conjugate(RDC) Segment by Type

- 2.2.1 Therapy
- 2.2.2 Diagnosis
- 2.2.3 Radionuclide Drug Conjugate(RDC) Market Size by Type
 - 2.2.3.1 Radionuclide Drug Conjugate(RDC) Market Size CAGR by Type (2021 VS 2025 VS 2032)
 - 2.2.3.2 Global Radionuclide Drug Conjugate(RDC) Market Size Market Share by Type (2021-2026)

2.3 Radionuclide Drug Conjugate(RDC) Segment by Application

- 2.3.1 Prostate Cancer
- 2.3.2 Neuroendocrine Cancer
- 2.3.3 Other
- 2.3.4 Radionuclide Drug Conjugate(RDC) Market Size by Application
 - 2.3.4.1 Radionuclide Drug Conjugate(RDC) Market Size CAGR by Application (2021 VS 2025 VS 2032)
 - 2.3.4.2 Global Radionuclide Drug Conjugate(RDC) Market Size Market Share by Application (2021-2026)

3 RADIONUCLIDE DRUG CONJUGATE(RDC) MARKET SIZE BY PLAYER

3.1 Radionuclide Drug Conjugate(RDC) Market Size Market Share by Player

3.1.1 Global Radionuclide Drug Conjugate(RDC) Revenue by Player (2021-2026)

3.1.2 Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Player (2021-2026)

3.2 Global Radionuclide Drug Conjugate(RDC) Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 RADIONUCLIDE DRUG CONJUGATE(RDC) BY REGION

4.1 Radionuclide Drug Conjugate(RDC) Market Size by Region (2021-2026)

4.2 Global Radionuclide Drug Conjugate(RDC) Annual Revenue by Country/Region (2021-2026)

4.3 Americas Radionuclide Drug Conjugate(RDC) Market Size Growth (2021-2026)

4.4 APAC Radionuclide Drug Conjugate(RDC) Market Size Growth (2021-2026)

4.5 Europe Radionuclide Drug Conjugate(RDC) Market Size Growth (2021-2026)

4.6 Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas Radionuclide Drug Conjugate(RDC) Market Size by Country (2021-2026)

5.2 Americas Radionuclide Drug Conjugate(RDC) Market Size by Type (2021-2026)

5.3 Americas Radionuclide Drug Conjugate(RDC) Market Size by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Radionuclide Drug Conjugate(RDC) Market Size by Region (2021-2026)

- 6.2 APAC Radionuclide Drug Conjugate(RDC) Market Size by Type (2021-2026)
- 6.3 APAC Radionuclide Drug Conjugate(RDC) Market Size by Application (2021-2026)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia

7 EUROPE

- 7.1 Europe Radionuclide Drug Conjugate(RDC) Market Size by Country (2021-2026)
- 7.2 Europe Radionuclide Drug Conjugate(RDC) Market Size by Type (2021-2026)
- 7.3 Europe Radionuclide Drug Conjugate(RDC) Market Size by Application (2021-2026)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Radionuclide Drug Conjugate(RDC) by Region (2021-2026)
- 8.2 Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size by Type (2021-2026)
- 8.3 Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size by Application (2021-2026)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 GLOBAL RADIONUCLIDE DRUG CONJUGATE(RDC) MARKET FORECAST

10.1 Global Radionuclide Drug Conjugate(RDC) Forecast by Region (2027-2032)

10.1.1 Global Radionuclide Drug Conjugate(RDC) Forecast by Region (2027-2032)

10.1.2 Americas Radionuclide Drug Conjugate(RDC) Forecast

10.1.3 APAC Radionuclide Drug Conjugate(RDC) Forecast

10.1.4 Europe Radionuclide Drug Conjugate(RDC) Forecast

10.1.5 Middle East & Africa Radionuclide Drug Conjugate(RDC) Forecast

10.2 Americas Radionuclide Drug Conjugate(RDC) Forecast by Country (2027-2032)

10.2.1 United States Market Radionuclide Drug Conjugate(RDC) Forecast

10.2.2 Canada Market Radionuclide Drug Conjugate(RDC) Forecast

10.2.3 Mexico Market Radionuclide Drug Conjugate(RDC) Forecast

10.2.4 Brazil Market Radionuclide Drug Conjugate(RDC) Forecast

10.3 APAC Radionuclide Drug Conjugate(RDC) Forecast by Region (2027-2032)

10.3.1 China Radionuclide Drug Conjugate(RDC) Market Forecast

10.3.2 Japan Market Radionuclide Drug Conjugate(RDC) Forecast

10.3.3 Korea Market Radionuclide Drug Conjugate(RDC) Forecast

10.3.4 Southeast Asia Market Radionuclide Drug Conjugate(RDC) Forecast

10.3.5 India Market Radionuclide Drug Conjugate(RDC) Forecast

10.3.6 Australia Market Radionuclide Drug Conjugate(RDC) Forecast

10.4 Europe Radionuclide Drug Conjugate(RDC) Forecast by Country (2027-2032)

10.4.1 Germany Market Radionuclide Drug Conjugate(RDC) Forecast

10.4.2 France Market Radionuclide Drug Conjugate(RDC) Forecast

10.4.3 UK Market Radionuclide Drug Conjugate(RDC) Forecast

10.4.4 Italy Market Radionuclide Drug Conjugate(RDC) Forecast

10.4.5 Russia Market Radionuclide Drug Conjugate(RDC) Forecast

10.5 Middle East & Africa Radionuclide Drug Conjugate(RDC) Forecast by Region (2027-2032)

10.5.1 Egypt Market Radionuclide Drug Conjugate(RDC) Forecast

10.5.2 South Africa Market Radionuclide Drug Conjugate(RDC) Forecast

10.5.3 Israel Market Radionuclide Drug Conjugate(RDC) Forecast

10.5.4 Turkey Market Radionuclide Drug Conjugate(RDC) Forecast

10.6 Global Radionuclide Drug Conjugate(RDC) Forecast by Type (2027-2032)

10.7 Global Radionuclide Drug Conjugate(RDC) Forecast by Application (2027-2032)

10.7.1 GCC Countries Market Radionuclide Drug Conjugate(RDC) Forecast

11 KEY PLAYERS ANALYSIS

11.1 Novartis

- 11.1.1 Novartis Company Information
- 11.1.2 Novartis Radionuclide Drug Conjugate(RDC) Product Offered
- 11.1.3 Novartis Radionuclide Drug Conjugate(RDC) Revenue, Gross Margin and Market Share (2021-2026)
- 11.1.4 Novartis Main Business Overview
- 11.1.5 Novartis Latest Developments
- 11.2 Telix Pharmaceuticals
 - 11.2.1 Telix Pharmaceuticals Company Information
 - 11.2.2 Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Offered
 - 11.2.3 Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue, Gross Margin and Market Share (2021-2026)
 - 11.2.4 Telix Pharmaceuticals Main Business Overview
 - 11.2.5 Telix Pharmaceuticals Latest Developments
- 11.3 Lantheus
 - 11.3.1 Lantheus Company Information
 - 11.3.2 Lantheus Radionuclide Drug Conjugate(RDC) Product Offered
 - 11.3.3 Lantheus Radionuclide Drug Conjugate(RDC) Revenue, Gross Margin and Market Share (2021-2026)
 - 11.3.4 Lantheus Main Business Overview
 - 11.3.5 Lantheus Latest Developments
- 11.4 Curium
 - 11.4.1 Curium Company Information
 - 11.4.2 Curium Radionuclide Drug Conjugate(RDC) Product Offered
 - 11.4.3 Curium Radionuclide Drug Conjugate(RDC) Revenue, Gross Margin and Market Share (2021-2026)
 - 11.4.4 Curium Main Business Overview
 - 11.4.5 Curium Latest Developments
- 11.5 Yuanda Pharmaceuticals
 - 11.5.1 Yuanda Pharmaceuticals Company Information
 - 11.5.2 Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Offered
 - 11.5.3 Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue, Gross Margin and Market Share (2021-2026)
 - 11.5.4 Yuanda Pharmaceuticals Main Business Overview
 - 11.5.5 Yuanda Pharmaceuticals Latest Developments
- 11.6 China Tongfang Pharmaceuticals
 - 11.6.1 China Tongfang Pharmaceuticals Company Information
 - 11.6.2 China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Offered
 - 11.6.3 China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC)

Revenue, Gross Margin and Market Share (2021-2026)

11.6.4 China Tongfang Pharmaceuticals Main Business Overview

11.6.5 China Tongfang Pharmaceuticals Latest Developments

11.7 Dongcheng Pharmaceuticals

11.7.1 Dongcheng Pharmaceuticals Company Information

11.7.2 Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Offered

11.7.3 Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue, Gross Margin and Market Share (2021-2026)

11.7.4 Dongcheng Pharmaceuticals Main Business Overview

11.7.5 Dongcheng Pharmaceuticals Latest Developments

11.8 Kelun Biotech

11.8.1 Kelun Biotech Company Information

11.8.2 Kelun Biotech Radionuclide Drug Conjugate(RDC) Product Offered

11.8.3 Kelun Biotech Radionuclide Drug Conjugate(RDC) Revenue, Gross Margin and Market Share (2021-2026)

11.8.4 Kelun Biotech Main Business Overview

11.8.5 Kelun Biotech Latest Developments

11.9 Hengrui

11.9.1 Hengrui Company Information

11.9.2 Hengrui Radionuclide Drug Conjugate(RDC) Product Offered

11.9.3 Hengrui Radionuclide Drug Conjugate(RDC) Revenue, Gross Margin and Market Share (2021-2026)

11.9.4 Hengrui Main Business Overview

11.9.5 Hengrui Latest Developments

11.10 Bayer

11.10.1 Bayer Company Information

11.10.2 Bayer Radionuclide Drug Conjugate(RDC) Product Offered

11.10.3 Bayer Radionuclide Drug Conjugate(RDC) Revenue, Gross Margin and Market Share (2021-2026)

11.10.4 Bayer Main Business Overview

11.10.5 Bayer Latest Developments

11.11 Zhihe Biotechnology

11.11.1 Zhihe Biotechnology Company Information

11.11.2 Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Product Offered

11.11.3 Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Revenue, Gross Margin and Market Share (2021-2026)

11.11.4 Zhihe Biotechnology Main Business Overview

11.11.5 Zhihe Biotechnology Latest Developments

11.12 Fulian Pharmaceuticals

11.12.1 Fulian Pharmaceuticals Company Information

11.12.2 Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Offered

11.12.3 Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue, Gross Margin and Market Share (2021-2026)

11.12.4 Fulian Pharmaceuticals Main Business Overview

11.12.5 Fulian Pharmaceuticals Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Radionuclide Drug Conjugate(RDC) Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)

Table 2. Radionuclide Drug Conjugate(RDC) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Therapy

Table 4. Major Players of Diagnosis

Table 5. Radionuclide Drug Conjugate(RDC) Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)

Table 6. Global Radionuclide Drug Conjugate(RDC) Market Size by Type (2021-2026) & (\$ millions)

Table 7. Global Radionuclide Drug Conjugate(RDC) Market Size Market Share by Type (2021-2026)

Table 8. Radionuclide Drug Conjugate(RDC) Market Size CAGR by Application (2021 VS 2025 VS 2032) & (\$ millions)

Table 9. Global Radionuclide Drug Conjugate(RDC) Market Size by Application (2021-2026) & (\$ millions)

Table 10. Global Radionuclide Drug Conjugate(RDC) Market Size Market Share by Application (2021-2026)

Table 11. Global Radionuclide Drug Conjugate(RDC) Revenue by Player (2021-2026) & (\$ millions)

Table 12. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Player (2021-2026)

Table 13. Radionuclide Drug Conjugate(RDC) Key Players Head office and Products Offered

Table 14. Radionuclide Drug Conjugate(RDC) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 15. New Products and Potential Entrants

Table 16. Mergers & Acquisitions, Expansion

Table 17. Global Radionuclide Drug Conjugate(RDC) Market Size by Region (2021-2026) & (\$ millions)

Table 18. Global Radionuclide Drug Conjugate(RDC) Market Size Market Share by Region (2021-2026)

Table 19. Global Radionuclide Drug Conjugate(RDC) Revenue by Country/Region (2021-2026) & (\$ millions)

Table 20. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by

Country/Region (2021-2026)

Table 21. Americas Radionuclide Drug Conjugate(RDC) Market Size by Country (2021-2026) & (\$ millions)

Table 22. Americas Radionuclide Drug Conjugate(RDC) Market Size Market Share by Country (2021-2026)

Table 23. Americas Radionuclide Drug Conjugate(RDC) Market Size by Type (2021-2026) & (\$ millions)

Table 24. Americas Radionuclide Drug Conjugate(RDC) Market Size Market Share by Type (2021-2026)

Table 25. Americas Radionuclide Drug Conjugate(RDC) Market Size by Application (2021-2026) & (\$ millions)

Table 26. Americas Radionuclide Drug Conjugate(RDC) Market Size Market Share by Application (2021-2026)

Table 27. APAC Radionuclide Drug Conjugate(RDC) Market Size by Region (2021-2026) & (\$ millions)

Table 28. APAC Radionuclide Drug Conjugate(RDC) Market Size Market Share by Region (2021-2026)

Table 29. APAC Radionuclide Drug Conjugate(RDC) Market Size by Type (2021-2026) & (\$ millions)

Table 30. APAC Radionuclide Drug Conjugate(RDC) Market Size by Application (2021-2026) & (\$ millions)

Table 31. Europe Radionuclide Drug Conjugate(RDC) Market Size by Country (2021-2026) & (\$ millions)

Table 32. Europe Radionuclide Drug Conjugate(RDC) Market Size Market Share by Country (2021-2026)

Table 33. Europe Radionuclide Drug Conjugate(RDC) Market Size by Type (2021-2026) & (\$ millions)

Table 34. Europe Radionuclide Drug Conjugate(RDC) Market Size by Application (2021-2026) & (\$ millions)

Table 35. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size by Region (2021-2026) & (\$ millions)

Table 36. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size by Type (2021-2026) & (\$ millions)

Table 37. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size by Application (2021-2026) & (\$ millions)

Table 38. Key Market Drivers & Growth Opportunities of Radionuclide Drug Conjugate(RDC)

Table 39. Key Market Challenges & Risks of Radionuclide Drug Conjugate(RDC)

Table 40. Key Industry Trends of Radionuclide Drug Conjugate(RDC)

Table 41. Global Radionuclide Drug Conjugate(RDC) Market Size Forecast by Region (2027-2032) & (\$ millions)

Table 42. Global Radionuclide Drug Conjugate(RDC) Market Size Market Share Forecast by Region (2027-2032)

Table 43. Global Radionuclide Drug Conjugate(RDC) Market Size Forecast by Type (2027-2032) & (\$ millions)

Table 44. Global Radionuclide Drug Conjugate(RDC) Market Size Forecast by Application (2027-2032) & (\$ millions)

Table 45. Novartis Details, Company Type, Radionuclide Drug Conjugate(RDC) Area Served and Its Competitors

Table 46. Novartis Radionuclide Drug Conjugate(RDC) Product Offered

Table 47. Novartis Radionuclide Drug Conjugate(RDC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 48. Novartis Main Business

Table 49. Novartis Latest Developments

Table 50. Telix Pharmaceuticals Details, Company Type, Radionuclide Drug Conjugate(RDC) Area Served and Its Competitors

Table 51. Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Offered

Table 52. Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 53. Telix Pharmaceuticals Main Business

Table 54. Telix Pharmaceuticals Latest Developments

Table 55. Lantheus Details, Company Type, Radionuclide Drug Conjugate(RDC) Area Served and Its Competitors

Table 56. Lantheus Radionuclide Drug Conjugate(RDC) Product Offered

Table 57. Lantheus Radionuclide Drug Conjugate(RDC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 58. Lantheus Main Business

Table 59. Lantheus Latest Developments

Table 60. Curium Details, Company Type, Radionuclide Drug Conjugate(RDC) Area Served and Its Competitors

Table 61. Curium Radionuclide Drug Conjugate(RDC) Product Offered

Table 62. Curium Radionuclide Drug Conjugate(RDC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 63. Curium Main Business

Table 64. Curium Latest Developments

Table 65. Yuanda Pharmaceuticals Details, Company Type, Radionuclide Drug Conjugate(RDC) Area Served and Its Competitors

Table 66. Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product

Offered

Table 67. Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 68. Yuanda Pharmaceuticals Main Business

Table 69. Yuanda Pharmaceuticals Latest Developments

Table 70. China Tongfang Pharmaceuticals Details, Company Type, Radionuclide Drug Conjugate(RDC) Area Served and Its Competitors

Table 71. China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Offered

Table 72. China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 73. China Tongfang Pharmaceuticals Main Business

Table 74. China Tongfang Pharmaceuticals Latest Developments

Table 75. Dongcheng Pharmaceuticals Details, Company Type, Radionuclide Drug Conjugate(RDC) Area Served and Its Competitors

Table 76. Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Offered

Table 77. Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 78. Dongcheng Pharmaceuticals Main Business

Table 79. Dongcheng Pharmaceuticals Latest Developments

Table 80. Kelun Biotech Details, Company Type, Radionuclide Drug Conjugate(RDC) Area Served and Its Competitors

Table 81. Kelun Biotech Radionuclide Drug Conjugate(RDC) Product Offered

Table 82. Kelun Biotech Radionuclide Drug Conjugate(RDC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 83. Kelun Biotech Main Business

Table 84. Kelun Biotech Latest Developments

Table 85. Hengrui Details, Company Type, Radionuclide Drug Conjugate(RDC) Area Served and Its Competitors

Table 86. Hengrui Radionuclide Drug Conjugate(RDC) Product Offered

Table 87. Hengrui Radionuclide Drug Conjugate(RDC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 88. Hengrui Main Business

Table 89. Hengrui Latest Developments

Table 90. Bayer Details, Company Type, Radionuclide Drug Conjugate(RDC) Area Served and Its Competitors

Table 91. Bayer Radionuclide Drug Conjugate(RDC) Product Offered

Table 92. Bayer Radionuclide Drug Conjugate(RDC) Revenue (\$ million), Gross Margin

and Market Share (2021-2026)

Table 93. Bayer Main Business

Table 94. Bayer Latest Developments

Table 95. Zhihe Biotechnology Details, Company Type, Radionuclide Drug Conjugate(RDC) Area Served and Its Competitors

Table 96. Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Product Offered

Table 97. Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 98. Zhihe Biotechnology Main Business

Table 99. Zhihe Biotechnology Latest Developments

Table 100. Fulian Pharmaceuticals Details, Company Type, Radionuclide Drug Conjugate(RDC) Area Served and Its Competitors

Table 101. Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Offered

Table 102. Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 103. Fulian Pharmaceuticals Main Business

Table 104. Fulian Pharmaceuticals Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Radionuclide Drug Conjugate(RDC) Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (2021-2032) (\$ millions)

Figure 6. Radionuclide Drug Conjugate(RDC) Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 7. Radionuclide Drug Conjugate(RDC) Sales Market Share by Country/Region (2025)

Figure 8. Radionuclide Drug Conjugate(RDC) Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 9. Global Radionuclide Drug Conjugate(RDC) Market Size Market Share by Type in 2025

Figure 10. Radionuclide Drug Conjugate(RDC) in Prostate Cancer

Figure 11. Global Radionuclide Drug Conjugate(RDC) Market: Prostate Cancer (2021-2026) & (\$ millions)

Figure 12. Radionuclide Drug Conjugate(RDC) in Neuroendocrine Cancer

Figure 13. Global Radionuclide Drug Conjugate(RDC) Market: Neuroendocrine Cancer (2021-2026) & (\$ millions)

Figure 14. Radionuclide Drug Conjugate(RDC) in Other

Figure 15. Global Radionuclide Drug Conjugate(RDC) Market: Other (2021-2026) & (\$ millions)

Figure 16. Global Radionuclide Drug Conjugate(RDC) Market Size Market Share by Application in 2025

Figure 17. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Player in 2025

Figure 18. Global Radionuclide Drug Conjugate(RDC) Market Size Market Share by Region (2021-2026)

Figure 19. Americas Radionuclide Drug Conjugate(RDC) Market Size 2021-2026 (\$ millions)

Figure 20. APAC Radionuclide Drug Conjugate(RDC) Market Size 2021-2026 (\$ millions)

Figure 21. Europe Radionuclide Drug Conjugate(RDC) Market Size 2021-2026 (\$ millions)

Figure 22. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size 2021-2026 (\$ millions)

Figure 23. Americas Radionuclide Drug Conjugate(RDC) Value Market Share by Country in 2025

Figure 24. United States Radionuclide Drug Conjugate(RDC) Market Size Growth 2021-2026 (\$ millions)

Figure 25. Canada Radionuclide Drug Conjugate(RDC) Market Size Growth 2021-2026 (\$ millions)

Figure 26. Mexico Radionuclide Drug Conjugate(RDC) Market Size Growth 2021-2026 (\$ millions)

Figure 27. Brazil Radionuclide Drug Conjugate(RDC) Market Size Growth 2021-2026 (\$ millions)

Figure 28. APAC Radionuclide Drug Conjugate(RDC) Market Size Market Share by Region in 2025

Figure 29. APAC Radionuclide Drug Conjugate(RDC) Market Size Market Share by Type (2021-2026)

Figure 30. APAC Radionuclide Drug Conjugate(RDC) Market Size Market Share by Application (2021-2026)

Figure 31. China Radionuclide Drug Conjugate(RDC) Market Size Growth 2021-2026 (\$ millions)

Figure 32. Japan Radionuclide Drug Conjugate(RDC) Market Size Growth 2021-2026 (\$ millions)

Figure 33. South Korea Radionuclide Drug Conjugate(RDC) Market Size Growth 2021-2026 (\$ millions)

Figure 34. Southeast Asia Radionuclide Drug Conjugate(RDC) Market Size Growth 2021-2026 (\$ millions)

Figure 35. India Radionuclide Drug Conjugate(RDC) Market Size Growth 2021-2026 (\$ millions)

Figure 36. Australia Radionuclide Drug Conjugate(RDC) Market Size Growth 2021-2026 (\$ millions)

Figure 37. Europe Radionuclide Drug Conjugate(RDC) Market Size Market Share by Country in 2025

Figure 38. Europe Radionuclide Drug Conjugate(RDC) Market Size Market Share by Type (2021-2026)

Figure 39. Europe Radionuclide Drug Conjugate(RDC) Market Size Market Share by Application (2021-2026)

Figure 40. Germany Radionuclide Drug Conjugate(RDC) Market Size Growth 2021-2026 (\$ millions)

Figure 41. France Radionuclide Drug Conjugate(RDC) Market Size Growth 2021-2026

(\$ millions)

Figure 42. UK Radionuclide Drug Conjugate(RDC) Market Size Growth 2021-2026 (\$ millions)

Figure 43. Italy Radionuclide Drug Conjugate(RDC) Market Size Growth 2021-2026 (\$ millions)

Figure 44. Russia Radionuclide Drug Conjugate(RDC) Market Size Growth 2021-2026 (\$ millions)

Figure 45. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size Market Share by Region (2021-2026)

Figure 46. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size Market Share by Type (2021-2026)

Figure 47. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size Market Share by Application (2021-2026)

Figure 48. Egypt Radionuclide Drug Conjugate(RDC) Market Size Growth 2021-2026 (\$ millions)

Figure 49. South Africa Radionuclide Drug Conjugate(RDC) Market Size Growth 2021-2026 (\$ millions)

Figure 50. Israel Radionuclide Drug Conjugate(RDC) Market Size Growth 2021-2026 (\$ millions)

Figure 51. Turkey Radionuclide Drug Conjugate(RDC) Market Size Growth 2021-2026 (\$ millions)

Figure 52. GCC Countries Radionuclide Drug Conjugate(RDC) Market Size Growth 2021-2026 (\$ millions)

Figure 53. Americas Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 54. APAC Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 55. Europe Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 56. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 57. United States Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 58. Canada Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 59. Mexico Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 60. Brazil Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 61. China Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 62. Japan Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 63. Korea Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 64. Southeast Asia Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 65. India Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 66. Australia Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 67. Germany Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 68. France Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 69. UK Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 70. Italy Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 71. Russia Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 72. Egypt Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 73. South Africa Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 74. Israel Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 75. Turkey Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

Figure 76. Global Radionuclide Drug Conjugate(RDC) Market Size Market Share Forecast by Type (2027-2032)

Figure 77. Global Radionuclide Drug Conjugate(RDC) Market Size Market Share Forecast by Application (2027-2032)

Figure 78. GCC Countries Radionuclide Drug Conjugate(RDC) Market Size 2027-2032 (\$ millions)

I would like to order

Product name: Global Radionuclide Drug Conjugate(RDC) Market Growth (Status and Outlook)
2026-2032

Product link: <https://marketpublishers.com/r/G16D51315A3FEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer
Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click
button on product page <https://marketpublishers.com/r/G16D51315A3FEN.html>